For the development of innovative products in therapeutic areas such as ophthalmology, respiratory and severe anti-infection, anti-tumor, Cerebro-cardiovascular first aid. The R&D center covers a building area of more than 13,000 square meters and is equipped with international advanced scientific research equipment and instruments. Our center is capable of conducting research and development of small molecule drugs, polypeptide drugs and high-end complex dosage forms. Our center has established characterization laboratories for pharmacodynamic evaluation of new drugs, thermal safety evaluation of processes, crystallization process and continuous flow process research. The R&D center has the qualifications of R&D innovative technology platforms at provincial level or above, such as National Enterprise Technology Center, Hubei Engineering and Technology Research Center for Ophthalmic Preparations, Hubei Engineering and Technology Research Center for Rare Disease Chemicals, etc. Our center also established a national post-doctoral research station.

Our focus is on the creation of mRNA drugs that are extremely potent in battling both tumors and infections. The R&D center is actively working on developing several innovative projects. This includes a platform for mRNA antigen design and optimization, an organ-targeted LNP technology, a pharmacology and toxicology R&D platform, and establishing a GMP-grade pilot R&D and production center. These initiatives are aimed at advancing the field and bringing about positive change. We are committed to pushing the boundaries of what is possible and making a tangible impact in the world. The facilitation of mRNA drug development, manufacturing, and clinical studies is made possible.

The R&D Center relies on the Australian National University and Griffith University for the development of anti-infective drugs based on glycomics technology. Griffith University is one of the few research institutions in the world focusing on glycomics and one of the largest scientific institutions in the field. The university specializes in the discovery and development of drugs, vaccines and diagnostics for infectious diseases worldwide, with over 200 clinical and basic scientific researchers and internationally renowned professors.

CardioNavi’s R&D Center in Shanghai was officially inaugurated, which mainly focuses on the research and development of mitral valve replacement products in the field of structural heart disease medical devices. The entire R&D center has a flow dynamics-fatigue testing area, mechanical performance testing area, valve processing and chemical testing area, equipped with imported advanced equipment such as stent laser cutting machine, valve laser cutting machine, valve accelerated fatigue testing machine, steady flow performance testing machine, and pulsating flow performance testing machine. It is the third international high-end medical device R&D center under the cerebro-cardiovascular precision interventional diagnosis and treatment segment, in addition to Wuhan Optics Valley Innovative Device R&D Center and Changzhou Innovative Device R&D Center, with “international technology to serve China” as its strategic core.

The institution was jointly established by Grand Pharma and Shandong University to conduct in-depth collaboration in the field of radiopharmaceutical R&D in product development, academic research, resource sharing as well as personnel training. The institute strengthens the R&D capabilities of our Radiopharmaceutical Diagnostic and Treatment Platform, improves the level of preclinical research and patent technical barriers, providing technical support and material conditions for the development of new products. The research institute is conducive to cultivating more high-end technical personnel and promoting the industrialization of scientific research achievements in the field of radiopharmaceuticals.

Wuhan Innovative Device Research and Development Center is a domestic R&D and production base for active devices in the Cerebro-cardiovascular Precision Interventional Diagnosis and Treatment Technology Segment. The R&D center occupies over 4,000 square meters of land with a Class 10,000 cleanliness-free room and a local Class 100 clean area, which can meet the production and assembly of Class III medical devices.